Compare PNRG & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNRG | NGNE |
|---|---|---|
| Founded | 1973 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 386.8M | 327.8M |
| IPO Year | 1995 | 2014 |
| Metric | PNRG | NGNE |
|---|---|---|
| Price | $272.50 | $28.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $160.00 | $63.57 |
| AVG Volume (30 Days) | 42.4K | ★ 130.0K |
| Earning Date | 04-16-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | ★ 10.86 | N/A |
| Revenue | ★ $189,052,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.18 | N/A |
| P/E Ratio | $24.34 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $126.40 | $14.65 |
| 52 Week High | $265.72 | $37.27 |
| Indicator | PNRG | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 71.14 | 51.76 |
| Support Level | $162.70 | $18.25 |
| Resistance Level | N/A | $29.05 |
| Average True Range (ATR) | 13.41 | 2.42 |
| MACD | 4.16 | -0.24 |
| Stochastic Oscillator | 90.31 | 37.54 |
PrimeEnergy Resources Corp is an independent oil and natural gas company that is engaged in acquiring, developing, and producing oil and natural gas. It owns producing and non-producing properties located in Texas and Oklahoma. The company's business activities include development and exploratory drilling and providing well servicing support operations for many of the onshore oil and gas wells through its subsidiaries. It is also active in the acquisition of producing oil and gas properties through joint ventures with industry partners.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.